Abstract
Background Untreated sleep disorders have been linked with type 2 diabetes in previous evidence. This study was to investigate the correlation between serum 25(OH) vitamin D level and sleep quality in elderly patients with type 2 diabetes and reveal the therapeutic potential of 25(OH) vitamin D-based treatments to improve sleeping quality and its effect on diabetes management.
Methods The sleep quality of 186 elderly patients with type 2 diabetes were assessed by questionaires of Pittsburgh sleep index (PSQI), with a cutoff point of PSQI • 7 defined as poor sleep. The measurement of serum 25(OH) vitamin D, fasting blood glucose, glycosylated hemoglobin, serum creatinine, total cholesterol, triglyceride, low-density lipoprotein cholesterol, and urinary albumin/creatinine ratio were collected. History of diabetic nephropathy, diabetic retinopathy, peripheral neuropathy, blood pressure, height, weight, hypoglycemic drug use, and the duration of diabetes also were recorded. Both univariate and multivariate logistic regression analysis was used to investigate the relationship of serum 25(OH) vitamin D and sleep quality in elderly patients with type 2 diabetes.
Results The age of elderly patients with type 2 diabetes was 73.6±4.3 years., and duration of diabetes was 8.8 ± 3.0 years. In the study, inadequate quality of sleep was reported in 63% elderly patients with type 2 diabetes. This study revealed that lower level of 25(OH) vitamin D was significantly associated with poor sleep quality in type 2 diabetes patients(P < 0.05). Multivariate logistic regression analysis showed that 25(OH) vitamin D deficiency and the use of insulin were risk factors for of inadequate sleep quality in elderly patients with type 2 diabetes.
Conclusions Elderly type 2 diabetic patients with 25(OH) vitamin D deficiency showed a high incidence of poor sleep quality, low-level of 25(OH) vitamin D was a risk factor for inadequate quality of sleep in elderly patients with type 2 diabetes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research received no external funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval: Informed consents of patients were obtained for diagnosis and treatment, and the study protocol was approved by the First Affiliated Hospital of University of Science and Technology of China. All the data received Institutional Review Board (IRB) approval by the Ethics Committee.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
slyyhongyan816{at}126.com
Danni.fan{at}nhs.net
lxf13751726381{at}163.com
yingqi{at}vip.126.com
xiyunjushi{at}163.com
Tony1982110{at}gmail.com
Data Availability
All the data was approved for use for this publication by First Affiliated Hospital of University of Science and Technology of China.
